Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues.

Current Oncology Reports
Valentina BracunRudolf A de Boer

Abstract

As the number of cancer survivors increases due to early screening and modern (antineoplastic) treatments, cancer treatment associated cardiotoxicity (CTAC) is becoming an increasing health burden that affects survival and quality of life among cancer survivors. Thus, clinicians need to identify adverse events early, in an effort to take suitable measures before the occurrence of permanent or irreversible cardiac dysfunction. Cardiac troponin (cTn) and B-type natriuretic peptide (BNP) have been proven to detect subclinical cardiotoxicity during antineoplastic treatment. As such, these cardio-specific biomarkers could predict which patients are at risk of developing CTAC even before the start of therapy. Nevertheless, there are inconsistent data from published studies, and the recommendations regarding the use of these biomarkers and their validity are mostly based on expert consensus opinion. In this review, we summarize available literature that evaluates biomarkers of CTAC, and we encourage strategies that integrate circulating biomarkers and cardiac imaging in identifying cancer patients that are at high risk.

References

Aug 10, 2000·Journal of the American College of Cardiology·D CardinaleC Fiorentini
Oct 28, 2010·Current Opinion in HIV and AIDS·Kyle Strimbu, Jorge A Tavel
Nov 22, 2011·Vascular Health and Risk Management·Asli Tanindi, Mustafa Cemri
Apr 30, 2014·Revista Española De Cardiología·Allan S Jaffe, Jordi Ordonez-Llanos
Oct 1, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Silvia RossiUNKNOWN EUROCARE-5 Working Group:
Oct 16, 2015·European Journal of Heart Failure·Wouter C MeijersW Frank Peacock
Nov 9, 2015·The Breast : Official Journal of the European Society of Mastology·I PalumboC Aristei
Dec 10, 2015·Vascular Health and Risk Management·Anne H BlaesDaniel Duprez
Feb 27, 2016·CA: a Cancer Journal for Clinicians·Giuseppe CuriglianoCarlo Maria Cipolla
Dec 31, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Betty R FerrellThomas J Smith
Jan 17, 2017·Expert Review of Molecular Diagnostics·Daniela CardinaleCarlo Maria Cipolla
Apr 22, 2017·The International Journal of Biological Markers·Francesca De IuliisSusanna Scarpa
Apr 24, 2017·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Hiromitsu KitayamaYasushi Tsuji
Jul 14, 2017·Chemotherapy·Pooja AdvaniJoseph L Blackshear
Aug 9, 2017·Cardiac Failure Review·Mark SweeneyAlexander R Lyon
Oct 11, 2017·Cardiovascular Research·Kyung Chan ParkMichael S Marber
Feb 21, 2018·Circulation·Wouter C MeijersRudolf A de Boer
Mar 15, 2018·Lancet·Javid J MoslehiDouglas B Johnson
Mar 16, 2018·Journal of the American College of Cardiology·Mônica Samuel AvilaEdimar Alcides Bocchi
Mar 24, 2018·Journal of the American College of Cardiology·Syed S MahmoodTomas G Neilan
Mar 24, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Daniela CardinaleUNKNOWN ICOS-ONE Study Investigators
Jun 2, 2018·European Journal of Heart Failure·Navin SuthaharRudolf A de Boer
Aug 22, 2018·Current Problems in Cancer·Elizabeth Riddell, Daniel Lenihan
Sep 8, 2018·European Journal of Heart Failure·Nilesh PareekAlexander R Lyon
Dec 21, 2018·Circulation·Kristian ThygesenUNKNOWN Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American He
Jan 10, 2019·Journal of the American College of Cardiology·Kai M EggersBertil Lindahl
Feb 5, 2019·Cardiovascular Research·Wouter C Meijers, Rudolf A de Boer
Mar 16, 2019·Journal of the American Heart Association·Eslam SamahaPeter Nagele

❮ Previous
Next ❯

Citations

May 17, 2021·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Veronique F KugenerMaxine Gossell-Williams
Jun 23, 2021·Cardio-Oncology·Rudolf A de BoerSherry-Ann Brown
Jan 8, 2022·American Journal of Therapeutics·Denisa-Corina CiuculeteGheorghe-Andrei Dan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Cardiotoxicity

Cardiotoxicity refers to the muscle damage or dysfunction of heart electrophysiology caused by drug intake or due to disease complications. It is a well-known side effect of several cytotoxic drugs, especially of the anthracyclines and can lead to long term morbidity. Here is the latest research.

Related Papers

Current Treatment Options in Cardiovascular Medicine
Li-Ling Tan, Alexander R Lyon
Expert Review of Molecular Diagnostics
Daniela CardinaleCarlo M Cipolla
Progress in Cardiovascular Diseases
Daniela Cardinale, Maria T Sandri
© 2022 Meta ULC. All rights reserved